Annual Licenses
Enterprise-grade solutions with predictable pricing and expert support. Fixed scope, no custom modifications—choose the tier that fits your needs.
Essential Network
3 payers of your choice, flat-rate, basic support
$65,000/year
Health Plan Coverage
3 payers of your choiceFull claims history 2016+Refreshed authorizationsAll lines of businessReal-time data with 99% successForward-Deployed Support
2-4 weeks of dedicated engineering support and onboardingCustom data mapping & code analysisImplementation planning & architecture reviewDedicated Slack support channelEnterprise Features
Unlimited FHIR API callsBAA includedStandard SLA guaranteesNote: Annual licenses are fixed-scope. For custom development, see Custom Infra Builds below.
Complete Network
400+ payers, 12 months history, manual session-based pulls.
$130,000/year
Health Plan Coverage
Full network of 400+ payers12-months claims history accessFull data pull from 1 EHROne-time authorizationsAll lines of businessReal-time data with 99% successForward-Deployed Support
2-4 weeks of dedicated engineering support and onboardingCustom data mapping & code analysisImplementation planning & architecture reviewDedicated Slack support channelEnterprise Features
Unlimited FHIR API callsBAA includedStandard SLA guaranteesPriority feature accessNote: Annual licenses are fixed-scope. For custom development, see Custom Infra Builds below.
Omni Network
Full historical data, persistent access, premium support
$250,000/year
Health Plan Coverage
Full network of 400+ payersFull claims history 2016+Full data pull from all EHRsTEFCA IAS access25,000 IAS verificationsRefreshed authorizationsAll lines of businessReal-time data with 99% successForward-Deployed Support
6-8 weeks of dedicated engineering support and onboardingCustom data mapping & code analysisImplementation planning & architecture reviewDedicated Slack support channelEnterprise Features
Unlimited FHIR API callsBAA includedPremium SLAsPriority feature accessAdvanced usage reportingGovernance tools (such as per-user audit trails, granular access logs)Note: Annual licenses are fixed-scope. For custom development, see Custom Infra Builds below.
Custom Services
Not ready or not a fit for an annual license? We offer custom services to meet your needs.
No-Code Field Test
We deliver real patient-consented claims records with zero engineering effort on your part to try before you buy.
Starts at $10,000
Field Test Overview
No-code data accessZero engineering requiredNo database or integration workReal-World Patient Data
5 real, consented patient recordsCoverage overview, EOBs, conditions, procedures, medicationsDelivered as flat files and raw FHIR dataSample includes patient demographics + plan detailsCustomizable User Criteria
Define recruitment parameters (e.g., diagnosis, insurer, plan type, meds)Flexpa handles recruiting and consentRecords matched to your use caseGuided Exploration
Personalized walkthrough recordingCallouts on data points relevant to your applicationOptional add-ons for more users or expanded attributes
Custom Infra Builds
Our annual licenses are standardized products with fixed scope. For bespoke development, integrations, or custom workflows—that's what Custom Infra Builds is for.
Hands-on support to build compliant, scalable healthcare integrations, leveraging Flexpa's interoperability expertise.
Custom pricing based on scope.
Interoperability
FHIR standards validation & testingHL7 Connectathon SupportPoC developmentSupport for SMART Health CardsDaVinci Payer to Payer Exchange testingCustom FHIR profile developmentIntegration with legacy systemsImplementation Support
Custom consent flowsTeam training & onboardingSuccess metrics & reportingDedicated project managementCustom workflow developmentTechnical documentation & training materialsCustomized AI modelsTrusted by healthcare leaders, trusted by patients
Frequently Asked Questions
“Flexpa's solution has been a game-changer for our decentralized clinical trials. The ability to seamlessly access and integrate health claims data has not only improved the quality of our studies but also enabled us to provide compelling evidence of the economic value of digital therapeutics.”
